CoronaryAtlas logo
CoronaryAtlas
Ceramide (24:1)
Pathway / Lipid retention & oxidation

Ceramide (24:1)

lipid

Ceramide (24:1) dysregulation predicts major adverse cardiovascular events through altered sphingolipid metabolism in atherosclerotic plaques.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleCeramide dysregulation in CAD progression; plaque lipid composition marker.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
67
A — assay feasibility
40
E — evidence strength
60
T1DI (composite)
12
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 1/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 14 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(1)